𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease

✍ Scribed by Hilary L. Tyne; Jan Parsons; Ann Sinnott; Susan H. Fox; Nicholas A. Fletcher; Malcolm J. Steiger

Publisher
Springer
Year
2004
Tongue
English
Weight
192 KB
Volume
251
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of long-term continuous subcuta
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
✍ Pedro J. García Ruiz; Ángel Sesar Ignacio; Begoña Ares Pensado; Alfonso Castro G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Abstract Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long‐term treated with CSAI. We reviewed data from 82 patie

Clozapine use in Parkinson's disease: A
Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
✍ Richard M. Trosch; Joseph H. Friedman; Meg C. Lannon; Rajesh Pahwa; D. Smith; La 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB

## Abstract We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participatin

Apomorphine monotherapy in the treatment
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
✍ Alice J. Manson; Kirsten Turner; Andrew J. Lees 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

Continuous subcutaneous infusion of apomorphine is now increasingly recognized as an effective treatment for refractory off periods and peak-dose dyskinesias in Parkinson's disease. We have reviewed our experience with apomorphine infusions, after a strategy decision in 1995 based on emerging precli

Long-term tolerability and efficacy of c
Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
✍ R. Inzelberg; P. Nisipeanu; M. J. Rabey; Prof. A. D. Korczyn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

## Abstract Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a

Long-term results of a multicenter study
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease
✍ Elena Moro; Andres M. Lozano; Pierre Pollak; Yves Agid; Stig Rehncrona; Jens Vol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract We report the 5 to 6 year follow‐up of a multicenter study of bilateral subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) in advanced Parkinson's disease (PD) patients. Thirty‐five STN patients and 16 GPi patients were assessed at 5 to 6 years aft